Thr566

Site Information
sNRPAsLtkDRLLAs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18007181

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 )
Disease tissue studied:	cervical cancer ( 5 ) , cervical adenocarcinoma ( 5 ) , melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 4 ) , HeLa S3 (cervical) ( 5 ) , liver ( 2 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 5 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
3	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
4	Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12 22067460 Curated Info
5	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info